Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia

Indian Journal of Urology

Volumn 28, Issue 4, 2012, Pages 377-381

  Manchanda, Parmeet Kaur ^a   Kibler, Aaron J ^b   Zhang, Mei ^a   Ravi, Janani ^c   Bid, Hemant K ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Benign prostatic hyperplasia; therapy; vitamin D receptor

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIINFLAMMATORY AGENT; CALCIFEDIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CH 5036249; CYPROTERONE ACETATE; ELOCALCITOL; FINASTERIDE; GONADORELIN AGONIST; HEXOKINASE INHIBITOR; OXYTOCIN ANTAGONIST; PHOSPHOTRANSFERASE INHIBITOR; RECOMBINANT GROWTH FACTOR; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR AGONIST;

ANTIANDROGEN THERAPY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CALCIUM HOMEOSTASIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL RESEARCH; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HYPERCALCEMIA; LOWER URINARY TRACT SYMPTOM; NONHUMAN; OVERACTIVE BLADDER; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE; PROSTATE HYPERTROPHY; PROSTATE SIZE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOM; URINARY TRACT DISEASE;

EID: 84873425458     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.105745     Document Type: Review

References (37)

1. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010;33:475-88
2. Bid HK, Konwar R, Singh V. Benign prostatic hyperplasia: Is it a growing public health concern for India? Indian J Med Sci 2008;62:373-4
3. Roehrborn CG. Benign prostatic hyperplasia: An overview. Rev Urol 2005;7:S3-14
4. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004;172:1784-91
5. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25 dihyroxyvitamin D3 on the primary cultures of human prostatic cells. Cancer Res 1994;54:805-10
6. Schatzl G, Gsur A, Bernhofer G, Haidinger G, Hinteregger S, Vutuc C, et al. Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urology 2001;57:567-72
7. Lin VK, Wang D, Lee IL, Vasquez D, Fagelson JE, McConnell JD. Myosin heavy chain gene Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1,25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005;68:1500-10
8. Taymans SE, Pack S, Pak E, Orban Z, Barsony J, Zhuang Z, et al. The human vitamin D receptor gene (VDR) is localized to region 12cen-q12 by fluorescent in situ hybridization and radiation hybrid mapping: Genetic and physical VDR map. J Bone Miner Res 1999;14:1163-6
9. Zamuda JM, Cauley JA, Ferrell RE. Molecular epidemiological of Vitamin D receptor variants. Epidemiol Rev 2000;22:203-17
10. Yi X, Yang P, Sun M, Yang Y, Li F. Decreased 1,25-Dihydroxyvitamin D3 level is involved in the pathogenesis of Vogt-Koyanagi-Harada (VKH disease. Mol Vis 2011;17:673-79
11. Na S, Ma Y, Zhao J, Schmidt C, Qing Q, Chandrasekhar S, et al. A Nonsecosteroidal Vitamin D Receptor Modulator Ameliorates Experimental Autoimmune Encephalomyelitis without Causing Hypercalcemia. Autoimmune Dis 2011;26:132958
12. Crescioli C, Morelli A, Adorini L, Ferruzzi P, Luconi M, Vannelli GB et al. Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab 2005;90:962-72
13. Samuel S, Sitrin MD. Vitamin D's role in cell proliferation and differentiation. Nutr Rev 2008;66:S116-24
14. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1,25-Didydroxyvitamin D3. Cancer Res 1992;52:515-20
15. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-60
16. Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P. Localization of 1,25-Dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol 1998;66:121-7
17. Li XY, Boudjelal M, Xiao JH, Peng ZH, Asuru A, Kang S, et al. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-Mediated degradation in human skin. Mol Endocrinol 1999;13:1686-94
18. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: Comparison with 1,25-Dihydroxyvitamin D3. Endocrinology 1995;136:20-6
19. Kim WT, Choi YD, Park C, Kim YW, Yun SJ, Kim IY, Kim WJ. Parathyroid hormone is not involved in prostate growth in patients with benign prostatic hyperplasia. Prostate 2011;71:1784-91
20. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004;338:143-56
21. Mishra DK, Bid HK, Srivastava DS, Mandhani A, Mittal RD. Association of vitamin D receptor gene polymorphism and risk of prostate cancer in India. Urol Int 2005;74:315-8
22. Bid HK, Mishra DK, Mittal RD. Vitamin-D receptor (VDR) gene (Fok-I, Taq-I and Apa-I) polymorphisms in healthy individuals from north Indian population. Asian Pac J Cancer Prev 2005;6:147-52
23. Konwar R, Chattopadhyay N, Bid HK. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia. BJU Int 2008;102:536-44
24. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000;60:305-8
25. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int 2002;68:226-31
26. Mullan RJ, Bergstralh EJ, Farmer SA, Jacobson DJ, Hebbring SJ, Cunningham JM, et al. Growth factor, cytokine, and vitamin D receptor polymorphisms and risk of benign prostatic hyperplasia in a community-based cohort of men. Urology 2006;67:300-5
27. Manchanda PK, Konwar R, Nayak VL, Singh V, Bid HK. Association of genetic variants of the vitamin D receptor (VDR) gene (Fok-I, Taq-I and Bsm-I) with susceptibility of benign prostatic hyperplasia in a North Indian population. Asian Pac J Cancer Prev 2010;11:1005-8
28. Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003;88:928-32
29. Tiwari A. Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. IDrugs 2009;12:381-93
30. Carlberg C, Molnar F. Current status of vitamin D signaling and its therapeutic applications. Curr Top Med Chem 2012;12:1-12
31. Adorini L, Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem Mol Biol 2007;103:689-93
32. Khadra A, Fletcher P, Luzzi G, Shattock R, Hay P. Interleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis. BJU Int 2006;97:1043-6
33. Adorini L, Penna G, Fibbi B, Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann N Y Acad Sci 2010;1193:146-52
34. Comeglio P, Chavalmane AK, Fibbi B, Filippi S, Marchetta M, et al. Human prostatic urethraexpresses vitamin D receptor and responds to vitamin D receptor ligation. J Endocrinol Invest 2010;33:730-8
35. Taniguchi K, Katagiri K, Kashiwagi H, Harada S, Sugimoto Y, Shimizu Y, et al. A novel nonsecosteroidal VDR agonist (CH5036249) exhibits efficacy in a spontaneous benign prostatic hyperplasia beagle model. J Steroid Biochem Mol Biol 2010;121:204-7
36. Wu-Wong JR, Tian J, Goltzman D. Vitamin D analogs as therapeutic agents: A clinical study update. Curr Opin Invest Drugs 2004;5:320-6
37. Hamid AR, Umbas R, Mochtar CA. Recent role of inflammation in prostate diseases: Chemoprevention development opportunity. Acta Med Indones 2011;43:59-65